Genflow Biosciences PLC Launches New Development Program
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), Europe's only public longevity company, has announced a new ophthalmology development program focusing on novel gene therapy using their proprietary Centenarian SIRT6 (cSIRT6) technology.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), Europe's only public longevity company, has announced a new ophthalmology development program focusing on novel gene therapy using their proprietary Centenarian SIRT6 (cSIRT6) technology.
The program will utilize a specially designed non-viral vector for precise delivery of SIRT6 to the eye, targeting ocular conditions including corneal pathologies and glaucoma. The company has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector.
According to CEO Dr. Eric Leire, the eye's closed and accessible compartment makes it an ideal target for gene therapy, with SIRT6 showing promising potential in treating corneal endothelial disorders and glaucoma.
Details
News Market Reaction – GENFF
The recorded move for GENFF in the trading session of this news was -2.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Genflow Biosciences Launches New Ophthalmology Development Program
Signs MTA with Leading Ophthalmology Company
LONDON, UK / ACCESS Newswire / April 10, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is excited to announce the launch of a new development program in ophthalmology, focused on advancing a novel gene therapy leveraging its proprietary Centenarian SIRT6 (cSIRT6). This therapy will utilize a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. The therapy is designed to combat ocular problems including several pathologies of the cornea and glaucoma.
This initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary Centenarian SIRT6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA) with a leading ophthalmology company, to collaborate on the design and development of the eye-targeted cSIRT6 non-viral vector to target ocular diseases. These therapies will leverage Genflow's proprietary SIRT6 Centenarian gene technology, in combination with an advanced vector delivery system.
Said Dr. Eric Leire, CEO of Genflow Biosciences: "We are thrilled to advance our ophthalmology program. The eye, as a closed and accessible compartment, presents an ideal target for gene therapy. More importantly, we believe that SIRT6 holds significant promise to transform the treatment landscape for corneal endothelial disorders and glaucoma."
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
|
Corporate Brokers |
|
Capital Plus Partners Ltd |
|
Jon Critchley, +44 0203 821 6168 |
|
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.